|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NMB |
Gene summary for NMB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NMB | Gene ID | 4828 |
| Gene name | neuromedin B | |
| Gene Alias | NMB | |
| Cytomap | 15q25.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P08949 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4828 | NMB | LZE4T | Human | Esophagus | ESCC | 4.10e-49 | 2.19e+00 | 0.0811 |
| 4828 | NMB | LZE7T | Human | Esophagus | ESCC | 6.86e-07 | 6.66e-01 | 0.0667 |
| 4828 | NMB | LZE20T | Human | Esophagus | ESCC | 3.35e-09 | 4.98e-01 | 0.0662 |
| 4828 | NMB | LZE22T | Human | Esophagus | ESCC | 7.33e-10 | 8.66e-01 | 0.068 |
| 4828 | NMB | LZE24T | Human | Esophagus | ESCC | 2.62e-07 | 3.64e-01 | 0.0596 |
| 4828 | NMB | P1T-E | Human | Esophagus | ESCC | 7.84e-10 | 6.11e-01 | 0.0875 |
| 4828 | NMB | P2T-E | Human | Esophagus | ESCC | 1.68e-14 | 2.94e-01 | 0.1177 |
| 4828 | NMB | P4T-E | Human | Esophagus | ESCC | 5.38e-63 | 1.97e+00 | 0.1323 |
| 4828 | NMB | P5T-E | Human | Esophagus | ESCC | 2.54e-23 | 6.82e-01 | 0.1327 |
| 4828 | NMB | P8T-E | Human | Esophagus | ESCC | 2.92e-27 | 5.41e-01 | 0.0889 |
| 4828 | NMB | P9T-E | Human | Esophagus | ESCC | 5.15e-61 | 1.65e+00 | 0.1131 |
| 4828 | NMB | P10T-E | Human | Esophagus | ESCC | 6.29e-13 | 3.09e-01 | 0.116 |
| 4828 | NMB | P11T-E | Human | Esophagus | ESCC | 1.08e-12 | 9.97e-01 | 0.1426 |
| 4828 | NMB | P12T-E | Human | Esophagus | ESCC | 1.54e-13 | 3.44e-01 | 0.1122 |
| 4828 | NMB | P15T-E | Human | Esophagus | ESCC | 1.58e-38 | 1.18e+00 | 0.1149 |
| 4828 | NMB | P16T-E | Human | Esophagus | ESCC | 1.06e-29 | 5.77e-01 | 0.1153 |
| 4828 | NMB | P17T-E | Human | Esophagus | ESCC | 1.13e-05 | 2.24e-01 | 0.1278 |
| 4828 | NMB | P19T-E | Human | Esophagus | ESCC | 6.56e-09 | 1.86e+00 | 0.1662 |
| 4828 | NMB | P20T-E | Human | Esophagus | ESCC | 6.95e-13 | 4.38e-01 | 0.1124 |
| 4828 | NMB | P21T-E | Human | Esophagus | ESCC | 5.48e-62 | 1.79e+00 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007099714 | Breast | IDC | neuron death | 57/1434 | 361/18723 | 1.31e-07 | 7.38e-06 | 57 |
| GO:190121414 | Breast | IDC | regulation of neuron death | 48/1434 | 319/18723 | 5.01e-06 | 1.69e-04 | 48 |
| GO:004211012 | Breast | IDC | T cell activation | 64/1434 | 487/18723 | 1.49e-05 | 3.77e-04 | 64 |
| GO:005086311 | Breast | IDC | regulation of T cell activation | 47/1434 | 329/18723 | 2.49e-05 | 5.91e-04 | 47 |
| GO:000164912 | Breast | IDC | osteoblast differentiation | 35/1434 | 229/18723 | 6.64e-05 | 1.35e-03 | 35 |
| GO:000715912 | Breast | IDC | leukocyte cell-cell adhesion | 49/1434 | 371/18723 | 1.27e-04 | 2.33e-03 | 49 |
| GO:000268311 | Breast | IDC | negative regulation of immune system process | 55/1434 | 434/18723 | 1.53e-04 | 2.67e-03 | 55 |
| GO:190303711 | Breast | IDC | regulation of leukocyte cell-cell adhesion | 45/1434 | 336/18723 | 1.72e-04 | 2.92e-03 | 45 |
| GO:00457651 | Breast | IDC | regulation of angiogenesis | 45/1434 | 342/18723 | 2.57e-04 | 3.98e-03 | 45 |
| GO:002240712 | Breast | IDC | regulation of cell-cell adhesion | 55/1434 | 448/18723 | 3.43e-04 | 5.07e-03 | 55 |
| GO:19013421 | Breast | IDC | regulation of vasculature development | 45/1434 | 348/18723 | 3.78e-04 | 5.38e-03 | 45 |
| GO:00703713 | Breast | IDC | ERK1 and ERK2 cascade | 43/1434 | 330/18723 | 4.28e-04 | 5.84e-03 | 43 |
| GO:000150311 | Breast | IDC | ossification | 50/1434 | 408/18723 | 6.51e-04 | 8.04e-03 | 50 |
| GO:190121513 | Breast | IDC | negative regulation of neuron death | 29/1434 | 208/18723 | 1.23e-03 | 1.32e-02 | 29 |
| GO:004209812 | Breast | IDC | T cell proliferation | 28/1434 | 199/18723 | 1.29e-03 | 1.35e-02 | 28 |
| GO:004212911 | Breast | IDC | regulation of T cell proliferation | 25/1434 | 171/18723 | 1.32e-03 | 1.38e-02 | 25 |
| GO:003264011 | Breast | IDC | tumor necrosis factor production | 25/1434 | 181/18723 | 2.92e-03 | 2.53e-02 | 25 |
| GO:003268011 | Breast | IDC | regulation of tumor necrosis factor production | 25/1434 | 181/18723 | 2.92e-03 | 2.53e-02 | 25 |
| GO:00071625 | Breast | IDC | negative regulation of cell adhesion | 37/1434 | 303/18723 | 3.27e-03 | 2.75e-02 | 37 |
| GO:007170611 | Breast | IDC | tumor necrosis factor superfamily cytokine production | 25/1434 | 186/18723 | 4.21e-03 | 3.31e-02 | 25 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NMB | insertion | Frame_Shift_Ins | novel | c.230_231insAGCATATAGTGTGTGCATTTTGAAGGGA | p.Arg78AlafsTer19 | p.R78Afs*19 | P08949 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| NMB | SNV | Missense_Mutation | c.365C>A | p.Pro122Gln | p.P122Q | P08949 | protein_coding | tolerated_low_confidence(0.25) | benign(0.005) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | |
| NMB | SNV | Missense_Mutation | novel | c.384N>C | p.Gln128His | p.Q128H | P08949 | protein_coding | tolerated_low_confidence(0.21) | benign(0.138) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NMB | SNV | Missense_Mutation | novel | c.418G>T | p.Val140Leu | p.V140L | P08949 | protein_coding | tolerated_low_confidence(0.59) | benign(0.001) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| NMB | SNV | Missense_Mutation | c.341N>A | p.Gly114Asp | p.G114D | P08949 | protein_coding | tolerated_low_confidence(0.12) | benign(0.058) | TCGA-BS-A0U7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NMB | SNV | Missense_Mutation | c.406N>A | p.His136Asn | p.H136N | P08949 | protein_coding | tolerated_low_confidence(0.05) | benign(0.015) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NMB | SNV | Missense_Mutation | c.388C>T | p.Arg130Cys | p.R130C | P08949 | protein_coding | tolerated_low_confidence(0.05) | benign(0.003) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NMB | SNV | Missense_Mutation | novel | c.455G>A | p.Cys152Tyr | p.C152Y | P08949 | protein_coding | deleterious_low_confidence(0.02) | benign(0.01) | TCGA-22-1002-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| NMB | SNV | Missense_Mutation | novel | c.83G>A | p.Ser28Asn | p.S28N | P08949 | protein_coding | tolerated(0.13) | benign(0.006) | TCGA-CN-5373-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NMB | SNV | Missense_Mutation | novel | c.289G>C | p.Ala97Pro | p.A97P | P08949 | protein_coding | deleterious(0.02) | possibly_damaging(0.735) | TCGA-CR-7364-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |